K40: A pilot study of targeted non-invasive ctDNA mutation tracking (applying molecular barcoding and high-depth plasma DNA NGS) in breast and colorectal cancer as a first proof of concept for the prospective prevention and early detection trial GEKKO.
Prof. Dr. Herrmann Brenner
Supported by: HIPO
Entity: breast cancer and colorectal cancer
Category: liquid biopsy project